March 27 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS
ASTRAZENECA - TOZORAKIMAB WAS GENERALLY WELL TOLERATED WITH A FAVOURABLE SAFETY PROFILE
ASTRAZENECA - TOZORAKIMAB DEMONSTRATES SIGNIFICANT REDUCTION IN COPD EXACERBATIONS IN TWO PHASE III TRIALS
ASTRAZENECA - FULL RESULTS FROM OBERON AND TITANIA TRIALS TO BE SHARED AT UPCOMING MEDICAL MEETING